Indivior Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $1.00M, a 0.00% change year-over-year.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.00M, a 50.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $1.00M.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $2.00M.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2025 was $2.00M, a 33.33% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $3.00M, a 0.00% change from fiscal 2023.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $3.00M, a 50.00% increase from fiscal 2022.
- Indivior Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $2.00M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $2.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.00M 10-Q · filed 2025-10-30 | |
| 2025-03-31 | $1.00M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $3.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.00M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $2.00M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $3.00M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $2.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |